Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Active not recruiting 3Terminated 1Completed 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5Sarcoma 4Tumor-Agnostic 1

Conditions

Multiple Myeloma 5

Interventions

Dexamethasone 124daratumumab 73Lenalidomide 72Bortezomib 61pomalidomide 45Cyclophosphamide 41carfilzomib 40Calcium Dobesilate 36Specimen Handling 34Biopsy 30Magnetic Resonance Spectroscopy 27belantamab mafodotin 24isatuximab 20fludarabine 20dexamethasone acetate 18dexamethasone 21-phosphate 18auricularum 18Melphalan 18talquetamab 16iberdomide 16fludarabine phosphate 12selinexor 11elotuzumab 10X-Rays 10tocilizumab 9Nivolumab 8Sirolimus 7Crizotinib 7trametinib 6Whole-Body Irradiation 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
nirogacestat × Plasma cell × 90 days × Clear all
NCT04722146 2026-06-05

MajesTEC-2

Janssen Research & Development, LLC

Phase 1 Active not recruiting
140 enrolled
Plasma cell

Multiple Myeloma

NCT04093596 2026-05-13

UNIVERSAL

Allogene Therapeutics

Phase 1 Completed
73 enrolled
Plasma cell

Multiple Myeloma

NCT04126200 2026-05-06

DREAMM 5

GlaxoSmithKline

Phase 1/2 Active not recruiting
208 enrolled 5 charts
Plasma cell

Multiple Myeloma

NCT07084896 2026-05-06

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

GlaxoSmithKline

Phase 1/2 Active not recruiting
106 enrolled 32 charts
Plasma cell

Multiple Myeloma

NCT05090566 2026-04-24

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Pfizer

Phase 2 Terminated
46 enrolled 15 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡